Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir,Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
1 University of Colorado Denver, Aurora, Colorado;2 Bristol-Myers Squibb, Hopewell, New Jersey;3 Fundación de Investigación, San Juan, Puerto Rico;4 Service d''Hépato-Gastroentérologie, CHU Henri Mondor, Créteil, France;5 The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas;6 Service d''Hépato-Gastroentérologie, Hôpital Saint Joseph, Marseille, France;7 University Hospital of Limoges, Limoges, France;8 Metropolitan Research, Arlington, Virginia;9 Miami Research Associates, South Miami, Florida;10 Options Health Research, Tulsa, Oklahoma;11 Hôpital Beaujon, Clichy, France;12 Université Paris Descartes, INSERM U1610 and Liver Unit, Hôpital Cochin, Paris, France;13 Mercy Medical Center, Baltimore, Maryland;14 Bristol-Myers Squibb, Princeton, New Jersey;15 Bristol-Myers Squibb, Wallingford, Connecticut
